Quote:
Originally Posted by Adder
Discovery? Not much. Mostly government-funded already.
Approval? With a changed incentive structure, we can likely streamline the approval process (some of which we should be doing anyway).
|
Um, no, drug discovery is not mostly government funded. Government funding would be one potential answer to what to do if Venture Capital and capital from Big Pharma leaves the field due to trim backs in patent exclusivity, but the numbers would be pretty sizable.
The second point is exactly the sort of thing that needs to be added to an M4A strategy if you're going to keep the innovative parts of our system. For example, its crazy that there are four or five key approval processes drugs need to run through to get widely distributed. We should be eliminating the US/EU/China/Japan/Canada duplication of efforts and creating common approval processes. At the least you should be able to use the same tests for each. This is not a discussion Bernie Bros engage in, because M4A solves everything and this isn't that.
